AA
CYTK icon

ALPS Advisors’s Cytokinetics CYTK Stock Holding History

ALPS Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-56,619
Closed -$3.11M – 1028
2025
Q3 		$3.11M Sell
56,619
-7,773
-12% -$320K 0.02% 321
2025
Q2 		$2.13M Buy
+64,392
New +$2.24M 0.01% 359
2023
Q2 		– Sell
-62,694
Closed -$2.21M – 1011
2023
Q1 		$2.21M Sell
62,694
-1,433
-2% -$58.5K 0.02% 268
2022
Q4 		$2.94M Buy
64,127
+12,727
+25% +$548K 0.03% 235
2022
Q3 		$2.49M Buy
51,400
+588
+1% +$28.3K 0.02% 265
2022
Q2 		$2M Sell
50,812
-35,396
-41% -$1.43M 0.02% 320
2022
Q1 		$3.17M Sell
86,208
-10,863
-11% -$386K 0.03% 158
2021
Q4 		$4.42M Sell
97,071
-5,283
-5% -$204K 0.05% 157
2021
Q3 		$3.66M Buy
102,354
+7,862
+8% +$231K 0.04% 195
2021
Q2 		$1.87M Sell
94,492
-34,160
-27% -$802K 0.02% 335
2021
Q1 		$2.99M Buy
128,652
+1,214
+1% +$25.9K 0.03% 217
2020
Q4 		$2.65M Buy
+127,438
New +$2.33M 0.03% 232

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ALPS Advisors's CYTK Position: Q4 2025 in Review

ALPS Advisors sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 56,619 shares — an estimated $3.11M sold.

ALPS Advisors first reported a position in CYTK in Q4 2020 and held it in 12 quarters. The position peaked at $4.42M in Q4 2021. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • ALPS Advisors reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 56,619 Cytokinetics shares in Q4 2025, an estimated $3.11M.
  • ALPS Advisors first reported a position in Cytokinetics in Q4 2020 and held it in 12 quarters.
  • ALPS Advisors's Cytokinetics position peaked at $4.42M in Q4 2021.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.